Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1034/j.1399-5618.2002.01182.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Combining treatments for migraine prophylaxis: the state-of-the-art.
J Headache Pain
December 2024
Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
Combination treatments for migraine prophylaxis present a promising approach to addressing the diverse and complex mechanisms underlying migraine. This review explores the potential of combining oral conventional prophylactics, onabotulinumtoxin A, monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway, and small molecule CGRP receptor antagonists (gepants). Among the most promising strategies, dual CGRP inhibition through mAbs and gepants may enhance efficacy by targeting both the CGRP peptide and its receptor, while the combination of onabotulinumtoxin A with CGRP treatments offers synergistic pain relief.
View Article and Find Full Text PDFEfficacy of Phenobarbital, Italept, and Topamax in the Treatment of Neonatal Seizures:A Double-Blinded Cross-Sectional Study of the Iranian Population.
Iran J Child Neurol
September 2024
Student research committee, Urmia university of medical sciences, Urmia ,Iran.
Objectives: Seizures are changes in the electrical activity of the brain. These changes can cause significant or otherwise asymptomatic symptoms. Phenobarbital and phenytoin are known drugs for treating neonatal seizures, but little clinical experience exists using other drugs.
View Article and Find Full Text PDFLong-term efficacy and safety of cannabidiol in patients with tuberous sclerosis complex: 3-year results from the cannabidiol expanded access program.
Epilepsia Open
October 2024
Jazz Pharmaceuticals, Inc, Carlsbad, California, USA.
Objective: The cannabidiol (CBD) Expanded Access Program provided compassionate access to CBD for patients with treatment-resistant epilepsy, including tuberous sclerosis complex (TSC), at 35 US epilepsy centers. Here, we present the long-term efficacy and safety outcomes for add-on CBD treatment in patients with TSC.
Methods: Patients received plant-derived, highly purified CBD (Epidiolex® 100 mg/mL, oral solution), increasing from 2 to 10 mg/kg/d to tolerance or maximum of 25-50 mg/kg/d.
Demonstration of Group-Level and Individual-Level Efficacy Using Time-to-Event Designs for Clinical Trials of Antiseizure Medications.
Neurology
August 2024
From the Department of Neurology (W.T.K., N.K., A.S.R., K.N.M., P.B.P.), and Department of Biomedical Informatics (W.T.K.), University of Pittsburgh, PA; Department of Neurology (W.T.K., N.K., A.S.R., W.S.), University of Michigan, Ann Arbor; Department of Neurology (W.T.K., J.M.S.), University of California, Los Angeles; Department of Biomedical Engineering (W.S.), University of Michigan, Ann Arbor; and Comprehensive Epilepsy Center (J.F.), New York University Grossman School of Medicine, New York.
Background And Objectives: Participants with treatment-resistant epilepsy who are randomized to add-on placebo and remain in a trial for the typical 3 to 5-month maintenance period may be at increased risk of adverse outcomes. A novel trial design has been suggested, time to prerandomization monthly seizure count (T-PSC), which would limit participants' time on ineffective therapy. We reanalyzed 11 completed trials to determine whether the primary efficacy conclusions at T-PSC matched each of the original, longer trials.
View Article and Find Full Text PDFPediatric Treatment-Resistant Obsessive Compulsive Disorder: Treatment Options and Challenges.
Paediatr Drugs
July 2024
Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, 1977 Butler Blvd, Suite 4-400, Houston, TX, 77030, USA.
Article Synopsis
- Pediatric OCD is a serious mental health condition that can be hard to treat, and about 10% of kids don't get better with standard treatments.
- Researchers looked at different ways to help those kids who don't respond to normal treatments, including learning from studies done on adults.
- The most promising options for treating these kids include special intensive programs and using certain medications alongside antidepressants, but more research is needed to find the best solutions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!